Back to results
US 7,605,150 B2Granted
Drug therapy for Celiac Sprue
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsChaitan Khosla, Felix Hausch
Life of this patent
Estimating the term…
Abstract
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
Claims5
A method of treating Celiac Sprue, the method comprising:
- administering to a patient an effective dose of a tTGase inhibitor having the formula
- wherein R1 is selected from the group consisting of PQP, Ac-PQP, PQPQLPYPQP (SEQ ID NO:21), Ac-PQPQLPFPQP (SEQ ID NO:22), QLQPFPQP (SEQ ID NO:23), LQLQPFPQPLPYPQP (SEQ ID NO:24);
- and
- R2 is selected from the group consisting of LPY, LPF-NH2, LPYPQPQLPY (SEQ ID NO:25), LPFPQPQLPF-NH2 (SEQ ID NO:26), LPYPQPQLP (SEQ ID NO:27), and LPYPQPQLPYPQPQPF (SEQ ID NQ:28)
- wherein said tTGase inhibitor attenuates gluten toxicity in said patient.
2 more elements
Dependencies are inferred from the claim text.